Table 1.

In vitro susceptibilities of 566 clinical isolates ofC. neoformans to voriconazole and itraconazole stratified by fluconazole susceptibility category

Fluconazole susceptibility category (μg/ml)aIsolate sourceNo. of isolates testedMIC (μg/ml)
ItraconazoleVoriconazole
RangeMIC50MIC90RangeMIC50MIC90
≤8.0Africa1540.06–0.50.250.50.015–0.250.120.12
United States321≤0.007–0.50.250.5≤0.007–0.120.060.06
All475≤0.007–0.50.250.5≤0.007–0.250.060.12
16–32Africa100.25–1.00.51.00.25–0.50.250.25
United States780.25–1.00.51.00.03–0.50.120.25
All880.25–1.00.51.00.03–0.50.120.25
≥64Africa
United States30.5–1.00.50.25–2.01.0
All30.5–1.00.50.25–2.01.0
 TotalAfrica1640.06–1.00.250.50.015–0.50.120.25
United States402≤0.007–1.00.250.5≤0.007–2.00.060.12
All566≤0.007–1.00.250.5≤0.007–2.00.060.12
  • a Fluconazole MICs ranged from 0.12 to >128 μg/ml with a MIC50 of 8.0 μg/ml (both United States and Africa) and a MIC90 of 16 μg/ml (United States, 16 μg/ml; Africa, 8.0 μg/ml).